The recent first global approval[1] of dupilumab in the US has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[2], based on the development milestones tracked in AdisInsight.[3] Continue reading “Dupilumab (Dupixant®): Follow up Approval in European Union”
The recent first global approval of tivozanib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.”
The recent first global approval[1] of avelumab in the US has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[2], based on the development milestones tracked in AdisInsight.[3] Continue reading “Avelumab (Bavencio®): Follow up Approvals in Europe and Japan”
The recent first global approval of glecaprevir/pibrentasvir has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Glecaprevir/Pibrentasvir (MAVIRET™): First Global Approval in Europe – then BAM! Anti-viral approval spreads rapidly across the globe!!”
The recent first global approval of pemafibrate has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Pemafibrate (Parmodia®): First Global Approval – second (PPAR)-α agonist joins Japanese market in a bid to tip the lipoprotein cholesterol balance”